GlassScriptPhysician profile
Phillip Glotser
NPI 1891100897
$4,719.73
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $1,649 · 2021: $2,280 · 2022: $615.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $886.87 | 2019-2022 | |
| Abbvie INC. | $735.30 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $414.57 | 2021-2022 | |
| Alkermes, INC. | $371.44 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $350.04 | 2019-2021 | |
| Bausch Health US, LLC | $335.39 | 2019-2021 | |
| Allergan, INC. | $225.78 | 2020-2021 | |
| Indivior INC. | $187.12 | 2020-2021 | |
| Amgen INC. | $176.64 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $139.49 | 2020-2022 | |
| Eisai INC. | $98.72 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $95.88 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $89.92 | 2019-2022 | |
| Lilly USA, LLC | $83.83 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $80.68 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $74.95 | 2021 | |
| Vanda Pharmaceuticals INC. | $72.40 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $63.70 | 2020-2021 | |
| Alfasigma USA, INC. | $57.92 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $50.48 | 2020-2021 | |
| Harmony Biosciences LLC | $30.73 | 2020-2021 | |
| Almatica Pharma LLC | $29.88 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $25.72 | 2021 | |
| Neurocrine Biosciences, INC. | $18.52 | 2020 | |
| Adlon Therapeutics L.P. | $12.03 | 2021 | |
| Lundbeck LLC | $11.73 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Glotser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.